Capsular contracture is the most common complication after breast implant surgery. It happens when the natural scar tissue your body forms around an implant thickens and tightens, squeezing the implant and changing how the breast looks and feels. Reported rates vary widely, from under 2% when modern prevention techniques are used to roughly 10 to 15% at six-year follow-up in large manufacturer studies, and even higher in some older data.
Why the Body Forms a Capsule
Every breast implant, regardless of type, triggers a normal immune response. Your body recognizes the implant as foreign and builds a thin shell of collagen fibers around it, much like it would around a splinter. In most people this capsule stays soft and flexible, and the breast feels natural. Capsular contracture is what happens when that process goes wrong: the collagen layer keeps thickening, contracts inward, and eventually compresses the implant.
The leading explanation centers on low-grade bacterial contamination. Bacteria can form a thin, sticky layer called a biofilm on the implant surface. Because the body can’t fully clear the biofilm, immune cells keep releasing inflammatory signals, which in turn stimulate more collagen production. The cycle feeds itself: persistent inflammation drives fibrosis, and the capsule progressively hardens.
Post-surgical fluid collections play into the same loop. Blood that pools around the implant (hematoma) or clear fluid buildup (seroma) both provide a nutrient-rich environment for bacteria and contain high concentrations of inflammatory molecules. Clinical data consistently link hematoma and seroma with higher contracture rates.
When Symptoms Typically Appear
Capsular contracture most commonly shows up between one and two years after surgery, though the timeline ranges widely. Some studies track onset anywhere from about 15 months to 8 years out. Cases that develop within the first six months are considered early onset and are less common, but they do occur. Surgeons grade the severity on a four-point scale known as the Baker classification:
- Grade I: The breast looks and feels normal. The capsule is soft.
- Grade II: The breast looks normal but feels slightly firm.
- Grade III: The breast feels firm and begins to look visibly distorted. Some discomfort is common.
- Grade IV: The breast is hard, painful, and clearly distorted. The implant may appear to sit high or look misshapen.
Grades I and II generally don’t require treatment. Grades III and IV are where most people seek help, because the firmness, visible changes, or pain interfere with daily comfort and appearance.
Risk Factors That Raise the Odds
Implant placement is one of the strongest predictors. A pooled analysis of multiple studies found that implants placed above the chest muscle (subglandular) carry more than double the risk of contracture compared with implants placed beneath the muscle (submuscular). The muscle layer may act as an additional barrier against bacterial migration from breast tissue to the implant surface.
Implant surface texture has been debated for years. Some older estimates assigned a 15% contracture risk to smooth implants versus about 5% for textured devices. However, more recent and larger studies paint a less clear-cut picture. A 10-year follow-up of one major implant line reported an 18.9% contracture rate for breast augmentation patients with no significant difference between smooth and textured surfaces. Another study found similar rates for smooth and textured implants when both were placed in the same plane. Newer “nanotextured” implants, which have an extremely light surface roughness, have reported rates as low as 1%, though longer-term data are still accumulating.
Other factors that increase risk include postoperative hematoma or seroma, surgical site infection, and revision surgery. Reconstruction patients tend to have higher contracture rates than cosmetic augmentation patients, likely because of factors like radiation exposure.
How Surgeons Try to Prevent It
Because bacterial contamination is the primary suspect, modern prevention strategies focus on keeping the implant as sterile as possible during placement. One widely adopted approach is the “no-touch technique,” which uses barriers to prevent the implant from contacting the patient’s skin on its way into the pocket. The most common tool for this is the Keller funnel, an FDA-cleared nylon sleeve with a slippery inner coating. The surgeon loads the implant into the funnel and squeezes it directly into the breast pocket without the implant ever touching gloves or skin edges.
Pocket irrigation is the other major preventive step. Surgeons rinse the implant pocket with antibiotic solutions, antiseptic solutions, or a combination of both before inserting the implant. Studies using triple-antibiotic irrigation have reported contracture rates as low as 1.8% in primary augmentation, a significant drop compared with historical averages. Submuscular placement rounds out the standard prevention bundle, given its demonstrated advantage over subglandular positioning.
Non-Surgical Treatment Options
For early or moderate contracture (Baker grade II or early III), medications originally developed for asthma have shown benefit. These drugs work by blocking inflammatory molecules involved in scar tissue formation. In one series of over 1,100 patients, those who developed grade III or IV contracture at three months were given an additional three months of medication, and their contracture improved, typically softening to a grade II. A separate study found that 75% of patients with early contracture experienced improvement or resolution after up to six months of medication, though liver function needs to be monitored during treatment.
These drugs tend to work best when contracture is caught early and the capsule hasn’t yet become thick or calcified. They are not reliably effective for long-standing, severe contracture.
Surgical Correction
When contracture reaches grade III or IV and isn’t responding to other measures, surgery is the standard path. The two main approaches differ significantly in how much tissue they remove and how extensive the recovery is.
An open capsulotomy involves cutting through the tightened capsule to release its grip on the implant, but the capsule tissue itself stays in the body. It’s a relatively quick procedure, typically 20 to 30 minutes per side, with minimal dissection and less postoperative pain. Because it preserves the existing capsule, there’s more remaining tissue to cushion the implant, and the risk of nerve injury is lower. For thin, non-calcified capsules, leaving the tissue in place appears to cause no harm.
A capsulectomy removes part or all of the hardened capsule. This is a more involved operation, adding roughly an hour of surgical time per side. The trade-off is that it removes the potentially infected or heavily scarred tissue entirely, which aligns with the biofilm theory of contracture. A capsulectomy is generally preferred when the capsule is thick or calcified, and it’s often combined with a change in implant pocket (for example, moving from above the muscle to below it) and placement of a new implant. The more extensive dissection means a longer recovery and slightly higher risk of complications like nerve damage or contour irregularities from reduced tissue coverage.
Some surgeons combine capsulectomy with the same prevention strategies used in first-time augmentation: pocket irrigation, no-touch insertion, and submuscular placement. The goal is to break the inflammatory cycle and reduce the chance of contracture recurring in the new pocket.